PCOS on the rise in young women: Are you at risk?

PCOS is increasingly affecting young women. Discover the key risk factors, symptoms, and management strategies to protect your health and well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ya7CcSh
via IFTTT

Read More

Sooji breakfast recipes: 5 healthy and easy options to try

Here are five healthy breakfast ideas using sooji (semolina):

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BVgCYqa
via IFTTT

Read More

Zydus Lifesciences gets warning letter from USFDA for its Jarod injectable unit

Zydus Lifesciences received a warning letter from the USFDA regarding its injectables manufacturing facility at Jarod, following an inspection in April 2024. The letter cites violations of cGMP regulations. Zydus must respond within 15 days and take remedial action. The warning limits new product launches, impacting business growth in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ufi6SM5
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system

Zydus Lifesciences Ltd has received USFDA approval to market its Scopolamine transdermal system, which helps prevent nausea and vomiting under various conditions, including after surgery and due to motion sickness. The product, with a dosage of 1 mg/3 days, will be manufactured in Ahmedabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kSlFUcB
via IFTTT

Read More

7 protein-packed dinners for healthy weight loss

These 7 high-protein dinner recipes, including grilled chicken salad, baked salmon, and quinoa bowls, are designed to help with weight loss by providing satisfying, nutrient-rich meals that support your goals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wb5dFV0
via IFTTT

Read More

Monkeypox RT-PCR Test: A step-by-step guide for accurate results

Discover how to accurately use the Monkeypox RT-PCR test kit: from sample collection to handling and lab processing. Ensure reliable results with these essential steps.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cowmiuJ
via IFTTT

Read More

Listeria infection: Symptoms, source, and prevention

Over 50 hospitalized and 9 deaths reported in a major Listeria outbreak. Contaminated deli meats are linked to the outbreak. Learn about symptoms and safety tips.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7a5fupW
via IFTTT

Read More

Want to purify your blood? Try these 6 foods

Discover 6 natural foods that can help purify your blood, removing toxins and improving circulation. From beetroot to turmeric, these everyday ingredients support detoxification and enhance overall health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SuOZPnU
via IFTTT

Read More

Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson to launch Bmab 1200, a biosimilar to Stelara, in Europe, the UK, Canada, and Japan. This deal resolves patent disputes and secures future market entry, pending regulatory approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31h8gKJ
via IFTTT

Read More

Indian pharma exporters feel pain on Bangladesh crisis

The political unrest and violence in Bangladesh are posing significant challenges for Indian pharmaceutical exporters, leading to stranded funds and concerns over financial stability. This situation threatens to impact medicine availability and healthcare services in Bangladesh. Despite the market's growth potential, many Indian companies are now hesitant to supply without advance payments, emphasising the importance of risk management in this unpredictable scenario.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VaBeDh5
via IFTTT

Read More

Hillhouse bids highest to buy healthcare BPO GeBBS from Chrys Cap for $870 mn

GeBBS Healthcare Solutions, a Los Angeles-based healthcare BPO firm, is nearing acquisition by Hillhouse Investment, which has offered about $870 million. The final decision is expected in two weeks as ChrysCapital holds another round of negotiations. The acquisition will potentially see industry veterans Gautam Barai and Gautam Narayan at the helm.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ac8Q2mK
via IFTTT

Read More

Sloth fever outbreak: Key facts on the deadly virus and should you be worried?

The Oropouche virus, also known as "sloth fever," is spreading in South America and the Caribbean. Transmitted by midges and mosquitoes, it causes symptoms similar to dengue and Zika, with no vaccine or specific treatment available.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y175rKt
via IFTTT

Read More

Fairfax, Bain look to buy Gujarat's API Company Farmson

Canadian billionaire Prem Watsa's Fairfax Group and Bain Capital are in competition for a buyout of Farmson Basic Drugs, a leading API maker in India valued at ₹4,000 crore. Founded in 1969, Farmson is a major paracetamol manufacturer with a revenue of ₹1,750 crore in FY24. The company's concentrated focus on paracetamol production is a strength, but limited R&D poses challenges for diversification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/euQimrX
via IFTTT

Read More

Bharat Biotech launches oral cholera vaccine Hillchol after positive phase 3 trial

Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high global demand for cholera vaccines, the company can produce up to 200 million doses annually. Phase 3 trials validated its safety and effectiveness. The vaccine is administered orally to individuals over one year old.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H3g9cIF
via IFTTT

Read More

India develops indigenous Monkeypox RT-PCR testing kit, gets CDSCO approval

India has successfully developed its own indigenous RT-PCR testing kit to combat Monkeypox. The kit, created by Siemens Healthineers, has received manufacturing approval from the Central Drugs Standard Control Organisation (CDSCO).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jkEF31M
via IFTTT

Read More

More fixed-dose combo drugs may enter ban list

The Indian government recently banned 156 fixed-dose combination drugs, citing health risks. An expert committee found these combinations lacking therapeutic justification. More FDCs are under review and could face imminent bans as part of ongoing evaluations to ensure public safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZW1Qoh2
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic drug

Alembic Pharmaceuticals has been granted final approval from the USFDA for its generic Betamethasone Valerate Foam, intended to treat moderate-to-severe psoriasis of the scalp. This medication is equivalent to Luxiq Foam by Norvium Bioscience. Alembic’s shares ended 0.97% lower at Rs 1,089.90 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NvMEqjc
via IFTTT

Read More

TB testing technology developed by ICMR's regional centre allows tests at Rs 35

ICMR has introduced a new CRISPR-based technology for detecting tuberculosis at a low cost. Capable of testing 1,500 samples in a short period, this system aims to address limitations of existing methods. ICMR plans to commercialise this technology, offering technical support and seeking partner organisations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vL0J2VM
via IFTTT

Read More

Pharma companies seek more time to implement revised norms on manufacturing practices

Schedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a prompt product recall system for products known or suspected to be defective. Pharma lobby groups have written to the health minister, seeking an extension of the December 2024 deadline to December 2026, citing lack of resources and challenges faced by the industry in implementing the revised norms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V4A2PCw
via IFTTT

Read More

India aims to lead next industrial revolution with biomanufacturing policy: DBT

India introduced the BioE3 policy to tackle challenges related to food, energy, and climate. Approved by the Union Cabinet, the policy focuses on enhancing innovation in biomanufacturing, covering everything from medicines to bio-plastics. The initiative is expected to create job opportunities and promote sustainable development. The policy aligns with India's aim to become a developed nation by 2047, providing alternatives to traditional resources and addressing environmental concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bLraidZ
via IFTTT

Read More

Danfoss India confident of doubling sales by 2025, company president says

Danfoss India, a subsidiary of the Denmark-based Danfoss Group, is experiencing significant growth in the Indian market and aims to double its sales by 2025. The Indian market is the fastest-growing region for Danfoss, driven by increased opportunities in energy efficiency and electrification. The company reported a 10.6% EBITDA margin for the first half of the year, down from 12.4% last year, with overall sales of €5 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jn7PNtl
via IFTTT

Read More

USFDA pulls up Eugia for manufacturing lapses, data accuracy at Hyderabad plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, citing significant manufacturing issues at its Telangana plant. The USFDA's inspection from January 22 to February 2, 2024, revealed problems including inaccurate production and process simulation data, falsified environmental monitoring records, and incomplete batch production and control records.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vt1BpDZ
via IFTTT

Read More

Revoke 18% GST on health and life insurance premium: TMC to Nirmala Sitharaman

TMC leader Derek O'Brien has urged Finance Minister Nirmala Sitharaman to remove the 18% GST on health and life insurance premiums at the upcoming GST Council meeting. He argues that the tax is a burden on the middle class and may discourage people from buying or renewing insurance. O'Brien cited a February 2024 report from the Standing Committee on Finance recommending a reduction in GST rates to make insurance more affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pxAW2q3
via IFTTT

Read More

Zydus Lifesciences acquires 50% stake in Sterling Biotech

Zydus Lifesciences entered a joint venture with Perfect Day by acquiring a 50% stake in Sterling Biotech. The collaboration aims to build a manufacturing facility for animal-free protein products, addressing global demand. This venture marks Zydus' entry into the biotech sector, focusing on health and nutrition solutions for lactose-intolerant consumers and those preferring animal-free options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KLn5ITj
via IFTTT

Read More

Zydus Lifesciences to acquire 50 pc stake in Sterling Biotech from Perfect Day

Zydus Lifesciences announced an agreement with Perfect Day Inc to acquire a 50 per cent stake in Sterling Biotech. The partnership aims to establish a manufacturing facility for animal-free protein production. This move signifies Zydus' expansion into specialized biotech products catering to health and nutrition markets, particularly for those preferring animal-free or lactose-intolerant options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mXOgoDy
via IFTTT

Read More

How to reduce belly fat without exercise

Losing belly fat without exercise is achievable through dietary adjustments, lifestyle changes, and mindful practices. Here are some effective strategies:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K2GfLaO
via IFTTT

Read More

Govt bans 156 fixed-dose combo drugs over risks

FDCs are medicines that combine two or more drugs into a single dosage. The union health and family welfare ministry on Thursday issued a gazette notification, prohibiting manufacture, sale and distribution of these medicines based on the recommendation of an expert panel that evaluated 324 FDCs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/98mzx2L
via IFTTT

Read More

B'desh upheaval takes a toll on medical tourism in India

The number of Bangladeshi patients visiting India for medical treatment has plummeted by up to 50% due to political unrest in Bangladesh. This downturn has impacted revenues for Indian hospitals. Pharma exports to Bangladesh are also at risk, as the country sources 30% of its pharmaceutical ingredients and raw materials from India, potentially affecting medication availability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4OfBgu8
via IFTTT

Read More

ICMR-led study estimates 10-year risk of developing heart disease in adults in India

An ICMR-led study has found that unemployed adults in India have a significantly higher risk of developing heart disease over the next decade. The research analyzed nearly 4,500 adults aged 40-69 years, showing that men and urban residents have higher risks. High blood sugar and obesity also contribute to increased cardiovascular risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Vv3FZJQ
via IFTTT

Read More

Struggling with monsoon joint pain? These foods can help

Here are eight foods that can help naturally reduce joint pain during the monsoon season:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hazv3NY
via IFTTT

Read More

Alkem arm ties up with Exactech for knee, hip replacement implants

Alkem Laboratories has announced a partnership through its subsidiary, Alkem MedTech, with US-based Exactech Inc to manufacture and market large joint implants in India. The deal grants Alkem MedTech marketing rights for Exactech's implant brands, including Truliant, Optetrak, and Logic Fit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dIxBQVv
via IFTTT

Read More

USFDA flags Telangana unit of Aurobindo Pharma arm

The letter, issued on August 15, was later made public by the USFDA, which stated that there was failure to ensure the accuracy of data in records for both production and process simulations, i.e. media fills. Media fill is a microbiological test to help prevent contamination during drug production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NHPy18o
via IFTTT

Read More

Scheme to bolster medical device industry to roll out soon: Pharma Secretary

The Department of Pharmaceuticals will launch a new scheme within a month to strengthen the domestic medical device industry, according to Secretary Arunish Chawla. The initiative, developed after extensive consultations, aims to reduce import reliance and promote self-reliance. The scheme has secured in-principle approval from the Finance Ministry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TSE3aNR
via IFTTT

Read More

Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity

Indoco Remedies Ltd was granted approval from the USFDA to sell its generic Lofexidine tablets, used for opioid withdrawal. This approval includes 180 days of market exclusivity. The company plans an immediate US launch, manufacturing the product in Goa. Expected sales are estimated at USD 15.59 million, with significant growth anticipated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r79GXut
via IFTTT

Read More

Mpox vaccine coming soon, says Covishield manufacturer SII's CEO Adar Poonawalla

Adar Poonawalla of the Serum Institute of India announced that the company was developing a Mpox vaccine, with results expected within a year. The government issued isolation guidelines for suspected cases, and the NIV in Pune tested samples. Experts highlighted concerns about the new CLADE 1B lineage but did not foresee a lockdown.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yEv0KkF
via IFTTT

Read More

Ipca Labs expects its US generics sales to touch $200 million soon

Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5h9bpUH
via IFTTT

Read More

Serum Institute says working to develop Monkeypox vaccine

The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern. The move came after a sudden increase in cases was recorded in parts of Africa. In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GYeiprF
via IFTTT

Read More

Bloated every morning? Try these home remedies for gas relief

Waking up with a bloated stomach can ruin your day. Morning gas, often caused by diet and stress, can be eased with natural remedies like ginger tea, warm lemon water, or fennel seeds for quick relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j4UAYb0
via IFTTT

Read More

Granules India gets USFDA nod for generic Glycopyrrolate oral solution

Granules Pharmaceuticals Inc, a subsidiary of Granules India, has received approval from the USFDA for a generic Glycopyrrolate oral solution meant for pediatric patients with neurological conditions associated with drooling. The medication is bioequivalent to Cuvposa Oral Solution by Merz Pharmaceuticals and has a strength of 1mg/5mL.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZqfeGoK
via IFTTT

Read More

Operation buyout: KKR, TPG, and other PE firms eye purchase of India's largest cardiac stent maker SMT

Morgan Stanley PE Asia and Samara Capital collectively own 49% of the company while Kotak Pre IPO Opportunities Fund holds 6%. The Kotadias, the company's promoters, own the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/13F4CcZ
via IFTTT

Read More

Health ministry approves 25% enhancement in security deployment at central hospitals

Amid protests following a trainee doctor's alleged rape and murder in Kolkata, the Health Ministry increased security at Union hospitals by 25%. Officials noted that existing state laws already protect healthcare workers. A new committee will examine hospital security and facilities. Authorities urged striking doctors to resume work to avoid affecting patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RerqNlC
via IFTTT

Read More

Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO

Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26. The company is also progressing with Pen-G commercialization and aims for an EBITDA margin of 21-22%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x5Pmwfy
via IFTTT

Read More

Indian govt needs to trim citizens' waist size for the sake of economy

India's Economic Survey 2023-24 warned that increasing obesity rates could hinder the country's economic potential. Experts urged the government to promote healthier lifestyles through better diet, physical activity, and monitoring of health parameters. Emphasizing waist circumference and BMI, they suggested that addressing obesity is crucial to reaping India's demographic dividend.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hy7qT3w
via IFTTT

Read More

PM Modi monitoring Mpox status; meeting takes stock of preparedness

Prime Minister Narendra Modi has been monitoring the Mpox situation with no current cases in the country. A high-level meeting assessed the risk of a major outbreak as low. Experts recommended screening travelers and using existing COVID-19 infrastructure to contain potential cases. Transparent reporting and international collaboration were emphasized.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aK3xu1Y
via IFTTT

Read More

Baba Ramdev criticises 'toxic' allopathy medicines that 'killed' millions of Indians

Baba Ramdev voiced his opposition to allopathy, claiming millions in India have died from synthetic drugs. At a press conference, he highlighted the need for medical autonomy and a swadeshi revolution through Patanjali to achieve economic and medical freedom. He accused foreign pharmaceutical companies of creating dependency on harmful medications and stressed the importance of natural healthcare practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4P7e6Du
via IFTTT

Read More

Pharma Department discusses 'dumping' with glovemakers

Domestic glovemakers alleged that gloves from countries like Thailand, Malaysia and China are being dumped in India under different non-medical product codes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/19HqnAo
via IFTTT

Read More

Ipca launches new topical therapy against diabetic foot ulcer

Ipca Laboratories introduced Diulcus, a topical gel designed to treat diabetic foot ulcers, priced at Rs 1365 per pack. The gel is based on repurposed beta blocker Esmolol. Approved after clinical trials, the product showed promising ulcer closure rates, with Ipca targeting a substantial market share within three years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uZ9mpIs
via IFTTT

Read More

Domestic pharmaceutical retail market grows 11 per cent in July

The domestic pharmaceutical retail market saw an impressive 11% growth in July, attributed to increased sales of anti-infectives and pain relief due to rising flu and viral infections. Antibiotic Augmentin led sales at Rs 72 crore and topped the charts. Overall market valued at Rs 2,22,906 crore, showing 7 per cent growth in June. Sun Pharma maintained a top position, with Indian companies growing at 11.4 per cent and MNCs at 10.2 per cent in July. Analysts predict a 10 per cent growth driven by demand for acute therapies like anti-infectives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vSwthmb
via IFTTT

Read More

Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fall

Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing compliance with regulatory standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9jPg7Sa
via IFTTT

Read More

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible by a skilled scientist. This decision dismisses the damages awarded in May and affects Pfizer’s ongoing patent infringement claims. The case, Wyeth LLC v. AstraZeneca Pharmaceuticals LP, was heard in the District of Delaware.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bQkDPxv
via IFTTT

Read More

Aurobindo may take its injectable unit public

Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NEiOlVA
via IFTTT

Read More

Nishkala Healthcare acquires Navi Mumbai's Suasth Hospital under IBC process

Nishkala Healthcare acquired Suasth Healthcare Foundation's 400-bed hospital in Navi Mumbai for Rs 189 crore under IBC. Funded through Rs 73 crore in equity and bank loans, the purchase follows the hospital's admission into insolvency. Nishkala aims to enhance the hospital’s value and expand into medical education.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JZlsSpE
via IFTTT

Read More

Alembic gets USFDA nod for generic medication

Alembic Pharmaceuticals announced approval from the USFDA to market Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis prophylaxis, equivalent to Pradaxa Capsules. The company now has 211 ANDA approvals. Shares closed 3.17% lower at Rs 1,076 on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ugt7MJ5
via IFTTT

Read More

Southern states witness majority heart transplants owing to more donations

Southern states in India lead in heart transplantation as per Notto data. Tamil Nadu topped the list at 70 transplants, followed by Karnataka, Maharashtra, Gujarat, and Telangana. South India receives more heart donations due to increased deceased donations. India recorded 1,099 heart donations in 2023, with Telangana leading at 252, followed by Tamil Nadu and Karnataka. Dr YK Misra noted the importance of deceased donors for heart transplants. He highlighted the need for amendments to organ transplant laws in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TaM8EzU
via IFTTT

Read More

Biocon arm's growth formula: US rollouts & debt reduction

Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ModbxCQ
via IFTTT

Read More

SSUHS signs MoU with Novo Nordisk Foundation

Srimanta Sankaradeva University of Health Sciences and Novo Nordisk Foundation signed an MoU to enhance Assam's health sector. The deal aims to improve nursing education, including an Education Innovation Unit and Simulation Lab. The partnership provides initial financial support of Rs 6 crore and promises further collaboration to improve nursing education and development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oOHmLUy
via IFTTT

Read More

Revenue of domestic API firms to see 7-8 pc increase by 2029: Report

The revenue of domestic active pharmaceutical ingredients (API) producers in India is projected to grow by 7-8% annually by 2029, according to a report by ICRA. The rating agency estimates that revenues will increase from USD 13-14 billion in 2023, driven by the pharmaceutical formulations industry and factors like an aging population, rising chronic diseases, and contract manufacturing demand. The operating profit margins of API firms are expected to improve in FY2025. Despite past challenges, including volatile earnings due to rising raw material costs and supply chain issues, the industry is poised for steady growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LqUdHJ9
via IFTTT

Read More

Dr Reddy's gets establishment inspection report from USFDA for Visakhapatnam units

Dr Reddy's Laboratories Ltd has obtained an Establishment Inspection Report from the USFDA for its Duvvada units, now classified as Voluntary Action Indicated. The units underwent an inspection from May 8 to May 17, 2024, which led to a Form 483 with observations. Dr Reddy’s planned to resolve the issues within the given time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AqXWD6l
via IFTTT

Read More

As monsoon takes hold, anti-infective, respiratory drugs' demand surges

Monsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase in Poractant Alfa usage. Anti-malaria medicines experienced significant growth, driven by seasonal patterns. Core therapeutic areas like cardiac, respiratory, and gastro contributed to the overall market growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xH9JzqL
via IFTTT

Read More

What not to drink: 7 beverages that can worsen fatty liver

If you're looking to manage or avoid fatty liver, it's important to be cautious about your drink choices. Here are seven drinks that are generally considered worse for fatty liver:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/egYRT6t
via IFTTT

Read More

At over 10 cr, India’s diabetic population is surging, yet the country lags behind in prescribing new medicines

Priya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor followed global guidelines, while the second used Indian ones, stabilizing her condition. The case underscores different diabetic treatment protocols and the importance of tailored patient care in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2wdsQBP
via IFTTT

Read More

Explore lesser-known Indian nuts: Chilgoza, Chiraunji & their benefits

India boasts a rich tradition of nuts in cooking and medicine. While almonds and cashews are common, lesser-known nuts like chilgoza and chiraunji offer unique flavors and significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FpzmhJD
via IFTTT

Read More

Hospital chain Medanta lines up Rs 1,200 crore for Mumbai entry

Global Health, operator of Medanta hospitals, is set to build a 500-bed super specialty hospital in Mumbai with an investment of ₹1,200 crore. The project, funded equally by debt and internal accruals, will be completed in 3-4 years. Medanta recently acquired the land in Oshiwara through a public auction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fdCMeVA
via IFTTT

Read More

Boost kidney health with these 7 detoxifying foods

Detoxifying your kidneys is important for overall health. Here are seven foods that are particularly beneficial for kidney health:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dQBwhRk
via IFTTT

Read More

India eases drug approval process, waives local trials for advanced therapies

In a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major international regulators (US, UK, Japan, Australia, Canada, EU). This move, aimed at expediting access to advanced therapies like CAR T-cell therapy and Sacituzumab govitecan, still ensures post-marketing surveillance by the CDSCO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jrOfeKl
via IFTTT

Read More

Biotech giant Amgen plans to open to technology & innovation centre in Hyderabad

US biotech giant Amgen announced plans to open a new technology and innovation site in Hyderabad, India. The site will be located in HITEC City and will occupy six floors of the RMZ Spire Tower. It is expected to be operational in Q4 2024 and has the potential to accommodate up to 3,000 people.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRoODCN
via IFTTT

Read More

Fortis Healthcare to buy out PE funds from diagnostics arm Agilus

Fortis Healthcare has acquired a 34% stake in Agilus Diagnostics from private equity firms Jacob Ballas and IFC. This transaction valued Agilus at around ₹5,000 crore and increased Fortis's holding from 57% to 91%. Agilus operates 413 laboratories and faced expansion challenges due to investors' reluctance and rising competition from new-age online players.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z95ukRJ
via IFTTT

Read More

Bajaj could make a difference in healthcare space

The Bajaj group's move into the hospital industry promises to influence the Indian healthcare sector. Private hospitals have shown growth and investor interest has risen post-pandemic. Bajaj plans to establish hospitals in metropolitan areas but will face significant hurdles such as high costs and a lack of medical professionals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5XqVdFj
via IFTTT

Read More

India waives clinical trial requirement for drugs approved in developed markets

India has waived clinical trial requirements for new drugs with significant therapeutic advances that have been approved in the US, UK, Japan, Australia, Canada, or the EU. The Central Drugs Standard Control Organisation (CDSCO) stated that this move aims to speed up drug availability, especially for rare diseases, pandemics, and special defence needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gDf06rm
via IFTTT

Read More

India's Fortis Healthcare chairman Ravi Rajagopal resigns

Ravi Rajagopal has resigned as chairman of Fortis Healthcare, effective Sept. 30, due to increased commitments in the U.K. and other regions. He will also step down from the Corporate Social Responsibility Committee. Rajagopal became chairman in June 2018 when Fortis was dealing with significant challenges, and he found his tenure personally fulfilling.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yp5NGrI
via IFTTT

Read More

BHU study on Covaxin had serious methodological flaws as per ICMR: Prataprao Jadhav

The Indian Council of Medical Research (ICMR) reviewed a study on the long-term safety of Covaxin in adults and adolescents, conducted by Banaras Hindu University, and found significant methodological flaws. Minister of State for Health Prataprao Jadhav informed the Rajya Sabha that the study lacked a control group of unvaccinated individuals, making it impossible to link reported events to the vaccine. The study, published in May, also lacked background rates and baseline participant information. ICMR has requested the removal of its acknowledgment from the study and asked the journal to retract the paper due to unsupported conclusions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ClH27uW
via IFTTT

Read More

Pharma industry urges govt for stable drug pricing policy

The Organisation of Pharmaceutical Producers of India (OPPI) has called for a stable and predictable drug pricing policy, urging the government to avoid using Para 19 of the Drug Pricing Control Order (DPCO), which allows significant price reductions in the public interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muJ9vQw
via IFTTT

Read More

Hamara Hospital! Bajaj plans a healthcare ride

The Bajaj Group, worth ₹1.46 lakh crore, initiated steps to venture into the healthcare industry by setting up hospitals in metros. Overseen by Nirav Bajaj, the project will be housed in a new company, with phased investments based on milestones. This marks the group's first major diversification since Rahul Bajaj's death in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EzQ1l3D
via IFTTT

Read More

New data reveals why patients from the US and UK are flocking to India for organ transplants

In 2023, India conducted 1,851 organ transplants for foreign nationals, accounting for nearly 10% of all transplants. The majority of these transplants took place in Delhi, Rajasthan, and West Bengal. Foreign patients primarily seek living donor transplants due to lower costs and strict vetting protocols. Deceased donations are rare and usually reserved for Indian recipients. India set records with over 1,000 deceased donors and 18,378 transplants, highlighting its growing role as a hub for organ transplants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ULAde19
via IFTTT

Read More

Sun Pharma's hair loss drug in the cross hairs in US

Leqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and Drug Administration (USFDA) last week. Sun Pharma has been making preparations for months to launch the drug in July, but an injunction motion by the American drugmaker lncyte Corporation in the US District Court for the District of New Jersey has put the brakes on the launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwrhX9v
via IFTTT

Read More

Bharat Biotech credited ICMR, NIV as Covaxin co-inventors after missing them initially: Government

Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for not mentioning the names of ICMR and NIV in the patent application, the Union Health and Family Welfare Minister gave a detailed reply. There was a joint Memorandum of Understanding (MoU) between ICMR, NIV and Bharat Biotech for the development of Covaxin, he said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yjXgSFt
via IFTTT

Read More

Sanofi gets drug regulator nod to market RSV therapy in India

French drugmaker Sanofi announced on Thursday that it has received approval from India's Central Drugs Standard Control Organization (CDSCO) to market its novel therapy, Beyfortus, in India. The therapy is aimed at protecting newborns and infants from respiratory syncytial virus (RSV).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0YUjf7
via IFTTT

Read More